NCT07657988招募中不适用
Patient and Clinician Reported Outcomes Among Patients With Actinic Keratosis Receiving Tirbanibulin for Large fiEld Application on the Face, in U.S Clinical pRactice Settings: A Pilot Initiative (CLEAR)
Avant Health LLC2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年4月2日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
The goal of this observational study is to learn about the effectiveness of tirbanibulin among adult subjects with actinic keratosis (AK) lesions in the face. The main question it aim to answer is:
How does tirbanibulin improve subject's overall appearance of the skin, improve how patient's skin looks, and improve patient's skin texture, in a 57-day observation period.
Participants already taking tirbanibulin as part of their regular medical care for AK will answer online survey questions at the beginning of the study and at Day 57.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with AK on the face.
- •Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
- •Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
- •Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
- •Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
- •Able to read and write in English.
- •Provide consent to participate in the study.
- •Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.
排除标准
- •Patients with any dermatological condition of the face that could interfere with clinical evaluations.
- •Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
- •Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
- •Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
- •Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Exploratory study to determine the tolerability and effectiveness of Tirbanibulin in the treatment of Actinic Cheilitis - Cheilitis trial2022-502807-31-00Technische Universitat Dresden20
招募中
不适用
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibNon-Small Cell Lung CancerNCT07374614Peking University Shenzhen Hospital20
尚未招募
3 期
A study to examine usefulness and safety of remibrutinib in patients with generalized myasthenia gravis.CTRI/2025/07/092102Novartis Healthcare Pvt Ltd180
招募中
2 期
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaNCT07290010Hebei Medical University Fourth Hospital25
尚未招募
不适用
A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell LymphomaMature B-Cell LymphomaNCT07525817Ou Bai, MD/PHD40